Xenon Financial Statements From 2010 to 2024

XENE Stock  USD 43.15  0.70  1.65%   
Xenon Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Xenon Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Xenon Pharmaceuticals financial statements helps investors assess Xenon Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Xenon Pharmaceuticals' valuation are summarized below:
Gross Profit
-96.3 M
Market Capitalization
3.3 B
Enterprise Value Revenue
10.9 K
Earnings Share
(2.81)
Quarterly Revenue Growth
(1.00)
There are over one hundred nineteen available fundamental gauges for Xenon Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Xenon Pharmaceuticals' prevalent performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 2.3 B. The current year's Enterprise Value is expected to grow to about 2.2 B

Xenon Pharmaceuticals Total Revenue

9.43 Million

Check Xenon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xenon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 6.7 M or Selling General Administrative of 48.9 M, as well as many indicators such as Price To Sales Ratio of 239, Dividend Yield of 0.0 or PTB Ratio of 3.18. Xenon financial statements analysis is a perfect complement when working with Xenon Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Xenon Pharmaceuticals Correlation against competitors.
For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.

Xenon Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding70.2 M66.9 M27.5 M
Slightly volatile
Total AssetsB964.8 M284.8 M
Slightly volatile
Short and Long Term Debt Total10 M10.9 M7.6 M
Slightly volatile
Other Current Liabilities18.2 M17.4 MM
Slightly volatile
Total Current Liabilities17.3 M27.3 M16.3 M
Pretty Stable
Total Stockholder Equity974.3 M927.9 M255.7 M
Slightly volatile
Other Liabilities606.2 K638.1 K7.2 M
Slightly volatile
Property Plant And Equipment Net19.8 M18.8 M6.3 M
Slightly volatile
Accounts PayableM8.6 M2.9 M
Slightly volatile
Cash156.1 M148.6 M70.8 M
Slightly volatile
Non Current Assets Total335.8 M319.8 M57 M
Slightly volatile
Cash And Short Term Investments670 M638.1 M224.7 M
Slightly volatile
Net Receivables872.3 K874 K744.8 K
Slightly volatile
Common Stock Total Equity1.3 B1.2 B399 M
Slightly volatile
Liabilities And Stockholders EquityB964.8 M284.8 M
Slightly volatile
Non Current Liabilities Total7.2 M9.6 M11.9 M
Slightly volatile
Other Current Assets6.3 MM2.5 M
Slightly volatile
Total Liabilities27.2 M36.9 M28.3 M
Pretty Stable
Property Plant And Equipment Gross17.3 M30.1 M14.6 M
Slightly volatile
Total Current Assets677.2 M645 M227.9 M
Slightly volatile
Common Stock1.5 B1.4 B427.9 M
Slightly volatile
Property Plant Equipment7.8 M7.5 M3.3 M
Slightly volatile
Capital Surpluse171.6 M163.4 M65.9 M
Slightly volatile
Long Term Debt Total11.7 M12.5 M8.8 M
Slightly volatile
Net Invested Capital974.3 M927.9 M258.8 M
Slightly volatile
Short and Long Term Debt2.9 M5.3 M2.5 M
Slightly volatile
Net Working Capital340.5 M617.7 M186.1 M
Slightly volatile
Short Term Debt1.2 M1.3 MM
Pretty Stable
Capital Stock783.5 M1.4 B483.1 M
Slightly volatile
Capital Lease Obligations7.4 M10.9 M3.3 M
Slightly volatile
Deferred Long Term Asset Charges190.4 K214.2 K233.2 K
Slightly volatile

Xenon Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.7 M3.5 M1.1 M
Slightly volatile
Selling General Administrative48.9 M46.5 M15.8 M
Slightly volatile
Other Operating Expenses224.8 M214.1 M66.7 M
Slightly volatile
Research Development175.9 M167.5 M50.5 M
Slightly volatile
Total Operating Expenses49.4 M46.5 M43.5 M
Slightly volatile
Cost Of Revenue175.9 M167.5 M45.6 M
Slightly volatile
Interest Income24.6 M23.4 M6.8 M
Slightly volatile
Reconciled Depreciation3.4 M3.2 M1.1 M
Slightly volatile
Selling And Marketing Expenses2.8 M3.2 M3.5 M
Slightly volatile

Xenon Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation34 M32.4 M7.9 M
Slightly volatile
Begin Period Cash Flow56.3 M57.2 M49 M
Slightly volatile
Depreciation3.7 M3.5 M1.2 M
Slightly volatile
Capital Expenditures5.9 M5.6 M1.7 M
Slightly volatile
End Period Cash Flow156.1 M148.6 M64.6 M
Slightly volatile
Sale Purchase Of Stock770.2 K810.8 K20.2 M
Pretty Stable
Issuance Of Capital Stock28 M29.5 M122.5 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio23922879.1359
Slightly volatile
PTB Ratio3.183.32023.5281
Slightly volatile
Days Sales Outstanding64.6734.3359.1759
Pretty Stable
Book Value Per Share14.5713.87267.1334
Slightly volatile
Stock Based Compensation To Revenue2.041.941.1035
Slightly volatile
Capex To Depreciation1.111.58631.2937
Slightly volatile
PB Ratio3.183.32023.5281
Slightly volatile
Payables Turnover10.1419.482712.0114
Slightly volatile
Sales General And Administrative To Revenue2.653.132.9833
Pretty Stable
Research And Ddevelopement To Revenue8.7410.099.7621
Pretty Stable
Capex To Revenue0.140.280.1778
Pretty Stable
Cash Per Share8.989.53948.0117
Very volatile
Days Payables Outstanding17.818.734666.0663
Pretty Stable
Current Ratio13.1823.648414.4754
Slightly volatile
Tangible Book Value Per Share14.5713.87267.1334
Slightly volatile
Receivables Turnover10.4511.028.9961
Slightly volatile
Graham Number30.6329.17415.9272
Slightly volatile
Shareholders Equity Per Share14.5713.87267.1334
Slightly volatile
Debt To Equity0.130.150.1629
Very volatile
Capex Per Share0.0840.0840.0739
Very volatile
Graham Net Net5.228.99795.7171
Slightly volatile
Revenue Per Share0.170.181.2455
Slightly volatile
Interest Debt Per Share0.0120.01260.2444
Pretty Stable
Debt To Assets0.080.09470.1023
Pretty Stable
Price Book Value Ratio3.183.32023.5281
Slightly volatile
Days Of Payables Outstanding17.818.734666.0663
Pretty Stable
Ebt Per Ebit1.180.85351.0745
Slightly volatile
Company Equity Multiplier1.731.03972.0429
Slightly volatile
Long Term Debt To Capitalization0.130.120.1251
Slightly volatile
Total Debt To Capitalization0.110.130.1394
Very volatile
Debt Equity Ratio0.130.150.1629
Very volatile
Quick Ratio13.2123.648414.5089
Slightly volatile
Net Income Per E B T0.80.99840.9857
Slightly volatile
Cash Ratio7.475.45026.3509
Pretty Stable
Days Of Sales Outstanding64.6734.3359.1759
Pretty Stable
Price To Book Ratio3.183.32023.5281
Slightly volatile
Fixed Asset Turnover0.610.644.3428
Slightly volatile
Debt Ratio0.080.09470.1023
Pretty Stable
Price Sales Ratio23922879.1359
Slightly volatile
Asset Turnover0.01370.01440.1411
Slightly volatile
Price Fair Value3.183.32023.5281
Slightly volatile

Xenon Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 B2.1 B664.6 M
Slightly volatile
Enterprise Value2.2 B2.1 B614.8 M
Slightly volatile

Xenon Fundamental Market Drivers

Cash And Short Term Investments638.1 M

Xenon Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Xenon Pharmaceuticals Financial Statements

Xenon Pharmaceuticals stakeholders use historical fundamental indicators, such as Xenon Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Xenon Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Xenon Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Xenon Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Xenon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue8.4 M7.2 M
Cost Of Revenue167.5 M175.9 M
Stock Based Compensation To Revenue 1.94  2.04 
Sales General And Administrative To Revenue 3.13  2.65 
Research And Ddevelopement To Revenue 10.09  8.74 
Capex To Revenue 0.28  0.14 
Revenue Per Share 0.18  0.17 
Ebit Per Revenue(15.74)(16.53)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:
Check out the analysis of Xenon Pharmaceuticals Correlation against competitors.
For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.81)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.19)
Return On Equity
(0.27)
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.